You just read:

New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression

News provided by

Amgen

10 Jun, 2016, 16:00 ET